S-1 Plus Cisplatin Combination Chemotherapy in Patients with Advanced Non–Small Cell Lung Cancer

DOI PDF 被引用文献15件
  • Yukito Ichinose
    1Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan;
  • Kozo Yoshimori
    2Department of Respiratory Organs, Fukujuji Hospital Anti-TB Association, Tokyo, Japan;
  • Hiroshi Sakai
    3Department of Respiratory Disease, Saitama Cancer Center, Saitama, Japan;
  • Yushi Nakai
    4Department of Internal Medicine, Sendai Kohsei Hospital, Miyagi, Japan;
  • Takahiko Sugiura
    5Department of Pulmonary Disease, Aichi Cancer Center, Aichi, Japan;
  • Masaaki Kawahara
    6Department of Internal Medicine, National Kinki Central Hospital for Chest Diseases, Osaka, Japan; and
  • Hisanobu Niitani
    7Tokyo Cooperative Oncology Group, Tokyo, Japan

抄録

<jats:title>Abstract</jats:title> <jats:p>Purpose: To evaluate the efficacy and toxicity of a novel combination chemotherapeutic regimen including cisplatin with an oral anticancer agent, S-1 that consisted of tegafur, 5-chloro-2, 4-dihydroxypyridine, and potassium oxonate, for non–small-cell lung cancer (NSCLC) patients.</jats:p> <jats:p>Experimental Design: In this phase II trial, patients with locally advanced and metastatic NSCLC were treated with the oral administration of S-1 at 40 mg/m2 twice a day for 21 consecutive days while cisplatin (60 mg/m2) was administered intravenously on day 8. This schedule was repeated every 5 weeks.</jats:p> <jats:p>Results: Of 56 patients enrolled in the study, 55 patients were eligible and analyzed. The median number of cycles administered was 3 (range, 1–12 cycles). Among these 55 patients, one complete response and 25 partial responses were observed with an overall response rate of 47% (95% confidence interval, 34–61%). The median survival time was 11 months and the 1-year survival rate was 45%. Hematologic toxicities of grades 3 and 4 included neutropenia (29%) and anemia (22%). No grade 4 nonhematologic toxicity was observed. Grade 3 toxicity included anorexia (13%), vomiting (7%), or diarrhea (7%).</jats:p> <jats:p>Conclusions: S-1 plus cisplatin combination chemotherapy showed a promising effectiveness with acceptable toxicity rates in patients with advanced NSCLC. These results warrant further investigations of this regimen including a randomized controlled trial for its use as a first line treatment for NSCLC.</jats:p>

収録刊行物

  • Clinical Cancer Research

    Clinical Cancer Research 10 (23), 7860-7864, 2004-12-01

    American Association for Cancer Research (AACR)

被引用文献 (15)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ